Androcur patients will have to attest that they are informed of the risks of tumor - the obs
As of July 1, any patient starting treatment with Androcur or his generics must be informed of the risk of a tumor linked to these drugs and benefit from a brain imaging examination, according to the drug agency.
"This information mainly concerns women, cyproterone acetate, an active ingredient for these drugs, being a minority prescribed to men, in particular for prostate cancer and sexual deviations (chemical castration for pedophilia and/or repeated rapes)" , explains to AFP Jean-Michel Race, endocrinologist, of the ANSM.
An information sheet on the risk of meningioma (most often benign tumor) of these drugs must now be given by prescribing doctors to their patients.
The latter will only be able to obtain these drugs in pharmacy on the compulsory presentation of an annual information certificate that they have signed as well as the prescribing doctor, from July 1 for new treatments and January 1, 2020 for renewals.
Intracranial tumors
The Androcur (Bayer Laboratory) and its generics prescribed to combat severe excessive hair (hirsutism) or, out of its official indication, for endometriosis or acne, can multiply up to 20 (after 5 years of treatment), and even more, the probability of intracranial tumors in women treated for a long time and high doses.
Find the other Amavea articles here
